Nov. 8, 2012
VisionCare Ophthalmic Technologies, Inc
., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the upcoming scientific and corporate presentations on its implantable telescope technology. The telescope implant is an integral component of a new patient care program called
which has been developed to improve vision and quality of life in patients with
end-stage age-related macular degeneration (AMD),
the most advanced form of AMD. Eligible patients must have associated central vision blindness and must have either stopped responding to AMD medications, or have a form of the disease for which no treatment is available.
Two podium presentations are scheduled as follows:
of Ophthalmology (AAO) Annual Meeting
– 13, 2012 – McCormick Place,
Ophthalmology Innovation Summit (OIS)
November 8, 2012
- Monday, November 12 Session: Late Breakers Symposium Topic: Implantable Miniature Telescope for AMDTime: 2:35 – 2:45 PM Presenter: Stephen S. Lane, MDLocation: McCormick Place, Grand Ballroom S100C
– Chicago Marriott Downtown Magnificent Mile,
At the AAO annual meeting, VisionCare is in Booth #2665 located in the South Building, Level 3, Hall A of McCormick Place.
About the CentraSight Treatment Program
The first-of-kind telescope implant is integral to a new patient care program,
for patients with end-stage macular degeneration. The CentraSight treatment program involves a patient management process and access to reimbursement information for patients and physicians. The telescope implantation is performed by a specially trained ophthalmic surgeon as an outpatient procedure.
Patients and physicians can find more information about the telescope implant and related treatment program at
About the Telescope Implant
The Implantable Miniature Telescope (by Dr.
) is indicated for monocular implantation to improve vision in patients greater than or equal to 75 years of age with stable severe to profound vision impairment (best-corrected distance visual acuity 20/160 to 20/800) caused by bilateral central scotomas (blind areas) associated with end-stage AMD. This level of visual impairment constitutes statutory (legal) blindness.
Smaller than a pea, the telescope is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation.